Literature DB >> 19134502

The impact of obesity on health care costs among persons with schizophrenia.

Lydia A Chwastiak1, Robert A Rosenheck, Joseph P McEvoy, T Scott Stroup, Marvin S Swartz, Sonia M Davis, Jeffrey A Lieberman.   

Abstract

BACKGROUND: Obesity is the second leading cause of preventable death in the United States and is twice as common among individuals with schizophrenia as the general population.
METHODS: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness, a multisite trial of antipsychotic pharmacotherapy in 1460 patients with schizophrenia, were used to examine the relationships between body mass index (BMI) and medical costs.
RESULTS: ANCOVA analyses found significant increases in both psychiatric and nonpsychiatric medication costs associated with increasing BMI and a significant, but smaller, difference in costs of outpatient medical-surgical service utilization: US$41 per month for morbidly obese patients compared to US$26 per month for patients of normal weight (F=2.4, P=.04). In multivariable logistic regression analyses, morbid obesity was associated with significantly increased odds of any outpatient medical-surgical service costs. When compared to observations of BMI>35, BMI observations within the normal range (18.5-24.9) were half as likely to be associated with any outpatient medical-surgical costs (OR=0.53; 95% CI=0.45, 0.63).
CONCLUSIONS: In this large sample of persons with schizophrenia, obesity was associated with increased outpatient general medical service and medication costs even after controlling for demographic characteristics and medical comorbidity, but the absolute dollar amount was small.

Entities:  

Mesh:

Year:  2008        PMID: 19134502      PMCID: PMC2660565          DOI: 10.1016/j.genhosppsych.2008.09.012

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  26 in total

1.  The effects of obesity, smoking, and drinking on medical problems and costs.

Authors:  Roland Sturm
Journal:  Health Aff (Millwood)       Date:  2002 Mar-Apr       Impact factor: 6.301

2.  National medical spending attributable to overweight and obesity: how much, and who's paying?

Authors:  Eric A Finkelstein; Ian C Fiebelkorn; Guijing Wang
Journal:  Health Aff (Millwood)       Date:  2003 Jan-Jun       Impact factor: 6.301

Review 3.  Economics and obesity: costing the problem or evaluating solutions?

Authors:  Larissa Roux; Cam Donaldson
Journal:  Obes Res       Date:  2004-02

4.  Mortality in a cohort of patients with schizophrenia: a record linkage study.

Authors:  S C Newman; R C Bland
Journal:  Can J Psychiatry       Date:  1991-05       Impact factor: 4.356

5.  A prospective study of obesity and risk of coronary heart disease in women.

Authors:  J E Manson; G A Colditz; M J Stampfer; W C Willett; B Rosner; R R Monson; F E Speizer; C H Hennekens
Journal:  N Engl J Med       Date:  1990-03-29       Impact factor: 91.245

6.  Health services use and health care costs of obese and nonobese individuals.

Authors:  Marsha A Raebel; Daniel C Malone; Douglas A Conner; Stanley Xu; Julie A Porter; Frances A Lanty
Journal:  Arch Intern Med       Date:  2004-10-25

7.  Weight gain as a risk factor for clinical diabetes mellitus in women.

Authors:  G A Colditz; W C Willett; A Rotnitzky; J E Manson
Journal:  Ann Intern Med       Date:  1995-04-01       Impact factor: 25.391

8.  Use of general medical services by VA patients with psychiatric disorders.

Authors:  Julie Cradock-O'Leary; Alexander S Young; Elizabeth M Yano; Mingming Wang; Martin L Lee
Journal:  Psychiatr Serv       Date:  2002-07       Impact factor: 3.084

9.  Prevalence and trends in obesity among US adults, 1999-2000.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

10.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  17 in total

1.  A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis.

Authors:  Christine L McKibbin; Shahrokh Golshan; Kathryn Griver; Katherine Kitchen; Thomas L Wykes
Journal:  Schizophr Res       Date:  2010-08       Impact factor: 4.939

2.  Barriers and facilitators of a healthy lifestyle among persons with serious and persistent mental illness: perspectives of community mental health providers.

Authors:  Christine L McKibbin; Katherine A Kitchen; Thomas L Wykes; Aaron A Lee
Journal:  Community Ment Health J       Date:  2014-07

3.  Expanding Cessation Pharmacotherapy Via Videoconference Educational Outreach to Prescribers.

Authors:  Mary F Brunette; Nino Dzebisashvili; Haiyi Xie; Sarah Akerman; Joelle C Ferron; Stephen Bartels
Journal:  Nicotine Tob Res       Date:  2015-08       Impact factor: 4.244

Review 4.  Antipsychotic drug treatment for elderly people with late-onset schizophrenia.

Authors:  Adib Essali; Ghassan Ali
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 5.  Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness.

Authors:  Ellen M Janssen; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Gen Hosp Psychiatry       Date:  2015-03-14       Impact factor: 3.238

6.  Association of psychiatric illness and all-cause mortality in the National Department of Veterans Affairs Health Care System.

Authors:  Lydia A Chwastiak; Robert A Rosenheck; Rani Desai; Lewis E Kazis
Journal:  Psychosom Med       Date:  2010-07-16       Impact factor: 4.312

Review 7.  Direct medical cost of overweight and obesity in the USA: a quantitative systematic review.

Authors:  A G Tsai; D F Williamson; H A Glick
Journal:  Obes Rev       Date:  2011-01       Impact factor: 9.213

Review 8.  Ziprasidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Sandra Schwarz; Paranthaman Seth S Bhoopathi; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

9.  Reliability and practicality of measuring waist circumference to monitor cardiovascular risk among community mental health center patients.

Authors:  Jessica Barber; Laura Palmese; Lydia A Chwastiak; Joseph C Ratliff; Erin L Reutenauer; Michel Jean-Baptiste; Cenk Tek
Journal:  Community Ment Health J       Date:  2013-01-10

10.  Body mass index and quality of life among outpatients with schizophrenia in Japan.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Yasushi Sato; Manabu Saito; Hanako Furukori; Taku Nakagami; Shuhei Kudo; Sunao Kaneko
Journal:  BMC Psychiatry       Date:  2013-04-09       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.